Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 12, 2016. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibilities (PDMR) in accordance with DTR 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of insider share acquisitions rather than a financial performance report.
Material Changes
No material changes to financial performance or business operations are reported in this filing. The document details specific share acquisitions by company leadership on May 11, 2016, executed through the GSK ShareReward Plan at a price of 1,476.34 pence per Ordinary Share.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It strictly reports the following share acquisitions:
- Sir Andrew Witty: 8 shares (personal) + 8 shares (matching)
- Dr P J T Vallance: 9 shares (personal) + 9 shares (matching)
- Other PDMRs (R G Connor, S Dingemans, N Hirons, S A Hussain, D S Redfern, C Thomas, P C Thomson, E Walmsley, V A Whyte): 8 shares (personal) + 8 shares (matching) each
Investor Verification Checklist
- Verify the share price of 1,476.34 pence against market data for May 11, 2016.
- Confirm the total number of shares acquired by each listed Director and PDMR.
- Review the terms of the GSK ShareReward Plan to understand the matching contribution structure.
- Note that this filing does not contain financial results; refer to the most recent Form 20-F or quarterly earnings release for financial metrics.